Drugs / Surotomycin
Surotomycin
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02835118 | Jul → Oct 2009 | Clostridium difficile colitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02835105 | Jan → Mar 2009 | Clostridium difficile colitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01085591 | Apr 2010 → Apr 2011 | Clostridium difficile colitis, diarrheal disease | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01598311 | May 2012 → Jul 2015 | Clostridium difficile colitis | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01597505 | May 2012 → Mar 2015 | Clostridium difficile colitis | Merck & Co., Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Surotomycin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02835118 ↗ |
| Known as | CB-183,315 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01598311 ↗ |
| Known as | Surotomicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2375161 ↗ |
| Known as | Surotomycine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2375161 ↗ |
| Modality | Peptide | “a novel bactericidal cyclic lipopeptide” PMID 28480267 ↗ Jan 2017 |
| Route | Oral | “administered orally” NCT01597505 ↗ |